US2020297677A1PendingUtilityA1
Compositions of citrulline
Assignee: HUBEI GRAND BIOTECHNOLOGY CO LTDPriority: Mar 19, 2019Filed: Dec 16, 2019Published: Sep 24, 2020
Est. expiryMar 19, 2039(~12.6 yrs left)· nominal 20-yr term from priority
Inventors:Hui Ouyang
A61K 31/198A23L 2/52A23L 33/10A61K 31/185A23V 2002/00A61K 9/0095A23L 33/16A61P 21/06A23L 33/175A61P 21/00
60
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present disclosure relates generally to supplement compositions containing citrulline and taurine at a weight ratio of 4.56:1 to 2.57:1 which have been demonstrated to have a pleasant flavor and can enhance the exercise endurance in individuals in a synergistic manner.
Claims
exact text as granted — not AI-modified1 . A solid composition comprising citrulline and taurine, wherein the citrulline and the taurine have a weight ratio of 5:1 to 1:5 and together constitute at least 55% w/w of the solid composition.
2 . The solid composition of claim 1 , wherein the citrulline and the taurine have a weight ratio of 5:1 to 1:1.
3 . The solid composition of claim 2 , which does not include more than 20% w/w of the combination of any other amino acid, vitamins, peptides, proteins, herb extracts, fatty acids, fibers, probiotics, glucosamine, chondroitin, and CoQ10.
4 . The solid composition of claim 3 , wherein the citrulline and the taurine have a weight ratio of 4:1 to 2.85:1.
5 . The solid composition of claim 3 , wherein the citrulline and the taurine have a weight ratio of 3.55:1 to 3:1.
6 . The solid composition of claim 3 , wherein the citrulline and the taurine have a weight ratio of 3.35:1 to 3.08:1.
7 . The solid composition of claim 3 , wherein the citrulline and the taurine together constitute at least 60% w/w of the solid composition.
8 . The solid composition of claim 3 , wherein the citrulline and the taurine together constitute at least 75% w/w of the solid composition.
9 . The solid composition of claim 1 , which is provided in the form of powders, tablets, granules, or capsules.
10 . The solid composition of claim 9 , wherein the tablets or granules are effervescent tablets or granules.
11 . A drink comprising citrulline and taurine, wherein the citrulline and the taurine have a weight ratio of 5:1 to 1:5 and together constitute at least 55% w/w of total solid ingredients dissolved in the drink.
12 . The drink of claim 11 , wherein the citrulline and the taurine have a weight ratio of 5:1 to 1:1.
13 . The drink of claim 11 , wherein the citrulline and the taurine have a weight ratio of 4:1 to 2.85:1.
14 . The drink of claim 11 , wherein the citrulline and the taurine have a weight ratio of 3.55:1 to 3:1.
15 . The drink of claim 11 , wherein the citrulline and the taurine have a weight ratio of 3.35:1 to 3.08:1.
16 . The drink of claim 12 , wherein the citrulline and the taurine together constitute at least 60% w/w of the total solid ingredients dissolved in the drink.
17 . The drink of claim 12 , wherein the citrulline and the taurine together constitute at least 75% w/w of the total solid ingredients dissolved in the drink.
18 . A method for treating hypertension or prehypertension in a mammalian subject, comprising orally administering to the subject the drink of claim 11 .
19 . The method of claim 18 , wherein about 0.1 g to about 100 g of the combination of citrulline and the taurine are administered daily.
20 . The method of claim 18 , wherein about 1 g to 10 g of the combination of citrulline and the taurine are administered daily.Join the waitlist — get patent alerts
Track US2020297677A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.